Speakers
Suzy Farid
Presentation
Suzanne Farid is Head of Department for UCL Biochemical Engineering, Professor of Bioprocess Systems Engineering, Co-Director of the EPSRC-funded Future Targeted Healthcare Manufacturing Hub, and Director of the UCL-AstraZeneca Centre of Excellence. She is a Fellow of the Royal Academy of Engineering (FREng) and a Fellow of Institution of Chemical Engineers (FIChemE).
Suzanne leads internationally in her research field on decisional tools to plan the best route to manufacture biotherapeutics. More specifically, she has pioneered algorithms to facilitate cost-effective and sustainable bioprocess design, capacity planning, R&D portfolio management, root cause analysis and manufacturability assessments for biopharmaceuticals ranging from mAbs to cell and gene therapies.
Suzanne’s expertise has been sought out in policy dialogues with UK Government bodies (e.g. G7 100 Days Mission roundtable) and global health agencies and invitations to chair the highest profile conference of the discipline (Recovery of Biological Products Conference RXIX) as well as international pioneering conferences in emerging areas (ECI Integrated Continuous Biomanufacturing ICB). Suzanne featured in The Manufacturer and KTN’s 30 Inspiring Women in Manufacturing in 2020 and the Medicine Maker Power List in 2017 and 2016. She sits on the UK BioIndustry Association Manufacturing Advisory Committee and ISCT Business Models & Investment Committee.
Suzanne joined UCL as a Lecturer in 2001. She obtained her Bachelor’s and Ph.D. degrees in Biochemical Engineering from UCL.
Catherine Green OBE is an Associate Professor in the Nuffield Department of Medicine at the University of Oxford. She heads the Clinical BioManufacturing Facility (CBF), the University’s GMP manufacturing facility for sterile biologics, where her mission is to translate innovative academic ideas into real world treatments.
During the COVID-19 pandemic Professor Green led on the initial GMP manufacturing delivering the Oxford–AstraZeneca adenovirus-vectored COVID-19 vaccine in record time. As well as SARS-CoV2, the CBF has made novel vaccines against other pathogens of global importance, including Malaria, Zika, Ebola, MERS, Rabies, Plague, Flu and TB, and they continue to develop vaccines and therapeutics for emerging pathogens, potential pandemic threats, bacterial pathogens, and cancer.